Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just ...
Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...
Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Hosted on MSN
Wedbush Downgrades Replimune Group (REPL)
Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17, ...
The FDA’s decision to reject Replimune’s (NASDAQ:REPL) lead asset RP1 for a type of skin cancer known as melanoma appears to have boosted its rival, Iovance Biotherapeutics (NASDAQ:IOVA), whose lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results